Câncer de próstata
Summary
Definition
History and exam
Key diagnostic factors
- presença de fatores de risco
- antígeno prostático específico (PSA) elevado
Other diagnostic factors
- exame de toque retal (ETR) anormal
- noctúria
- polaciúria
- hesitação urinária
- disúria
- hematúria
- perda de peso/anorexia
- letargia
- dor óssea
- linfonodos palpáveis
Risk factors
- idade >50 anos
- etnia negra
- Populações do norte da Europa, Caribe, Austrália, Nova Zelândia, América do Norte e sul da África
- história familiar positiva/fatores genéticos
- alimentação com alto teor de gordura
Diagnostic tests
1st tests to order
- antígeno prostático específico (PSA) sérico
- RNM multiparamétrica pré-biópsia
- biópsia de próstata
Tests to consider
- testes de biomarcadores pré-biópsia e calculadoras de risco
- testosterona
- TFHs
- Hemograma completo
- função renal
- cintilografia óssea (tecnécio-99)
- Tomografia computadorizada (TC)
- RNM
- antígeno de membrana específico da próstata (PSMA)-PET/CT
- PSMA-PET/MRI
- testes moleculares e genéticos de tumores
- avaliação genética e testes de linha germinativa
Treatment algorithm
doença de muito baixo risco
doença de baixo risco
doença de risco intermediário favorável
doença de risco intermediário desfavorável
doença de alto risco ou risco muito alto
doença não metastática: pós-prostatectomia radical
doença não metastática: pós-radioterapia
doença não metastática: resistente à castração
doença metastática: sensível à castração
doença metastática: resistente à castração
Contributors
Authors
Timothy J. Wallace, MD, PhD
Radiation Oncologist
Department of Radiation Oncology
Virginia Commonwealth University
Richmond
VA
Disclosures
TJW declares that he has no competing interests.
Mitchell S. Anscher, MD, FACR, FACRO, FASTRO
Professor Emeritus
Department of Radiation Oncology
Virginia Commonwealth University
Richmond
VA
Disclosures
MSA declares that he has no competing interests.
Peer reviewers
Emma Alexander, MBBS
Clinical Oncology Registrar
St Luke's Cancer Centre
Royal Surrey Hospital
Guildford
Surrey
UK
Disclosures
EA has received consultation fees from the following organisations: Blue Cross/Blue Shield Association, Sanofi-Aventis, Ferring Pharmaceuticals, Pfizer Corporation, American Urological Association, National Institutes of Health, Accreditation Council for Graduate Medical Education, Royal Hallamshire Hospital, Hartford County Medical Association. EA owns shares in Pfizer Pharmaceuticals, Johnson and Johnson, and General Electric Corporation.
Peter Albertsen, MD
Medical Director
UConn Medical Group
University of Connecticut Health Center
Farmington
CT
Disclosures
PA declares that he has no competing interests.
Patrick C. Walsh, MD
University Distinguished Service Professor of Urology
Professor Emeritus of Urology
Brady Urological Institute
Johns Hopkins University
Baltimore
MD
Disclosures
PCW declares that he has no competing interests.
James Kearns, MD
Assistant Professor of Urology
NorthShore University HealthSystem
Chicago
IL
Disclosures
JK declares that he has no competing interests. JK is an author of an article cited in the topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer [internet publication].Full text
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection [internet publication].Full text
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Sep;31(9):1119-34.Full text Abstract
Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018 Oct 11;36(34):JCO1801097.Full text Abstract
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024 Apr;211(4):509-17.Full text Abstract
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. J Urol. 2024 Apr;211(4):518-25.Full text Abstract
Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol. 2024 Apr;211(4):526-32.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Hiperplasia prostática benigna
- Prostatite crônica
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment breast, ovarian, pancreatic, and prostate
- NCCN clinical practice guidelines in oncology: prostate cancer early detection
More GuidelinesPatient information
Câncer de próstata
Câncer de próstata: perguntas a fazer ao seu médico
More Patient informationCalculators
Escore de sintomas prostáticos
More CalculatorsVideos
Cateterismo uretral masculino - Vídeo de demonstração
More videos
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer